Luveltamab Tazevibulin(Luveltamab Tazevibulin) - 药物靶点：FOLR1 x Tubulin_在研适应症：输卵管癌，卵巢上皮癌，铂耐药性卵巢癌_专利_临床

概要

基本信息

药物类型

ADC

别名

anti-FolRa ADC STRO-002、DBCO-Alexa647-conjugated SP7219、luvelta

+ [5]

靶点

FOLR1 x Tubulin

作用方式

拮抗剂、抑制剂

作用机制

FOLR1拮抗剂(叶酸受体α拮抗剂)、微管蛋白抑制剂

治疗领域

肿瘤内分泌与代谢疾病泌尿生殖系统疾病+ [3]

在研适应症

输卵管癌卵巢上皮癌铂耐药性卵巢癌+ [10]

非在研适应症-

原研机构

Sutro Biopharma, Inc.

在研机构

Sutro Biopharma, Inc.

Piramal Pharma Solutions, Inc.

天士力医药集团股份有限公司

非在研机构

天士力生物医药股份有限公司

最高研发阶段临床2/3期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评快速通道 (美国)、孤儿药 (美国)、罕见儿科疾病 (美国)

登录后查看时间轴

结构/序列

使用我们的ADC技术数据为新药研发加速。

登录

或

查看完整样例数据

Sequence Code 13410342L

来源: *****

Sequence Code 669201441H

来源: *****

关联

7

项与 Luveltamab Tazevibulin 相关的临床试验

NCT06679582

/ Recruiting临床1/2期

A Phase 1/2, Open-label Study Evaluating the Efficacy, Safety, and Pharmacokinetics (PK) of Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age with CBFA2T3::GLIS2 Acute Myeloid Leukemia (AML)

This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children. To be treated in this trial children must have a leukemia which did not respond or recurred after prior treatment. Luveltamab tazevibulin is an antibody-drug conjugate, which brings tazevibulin, an anticancer drug, to a molecule called FOLR1, present on the surface of CBFA2T3::GLIS2 AML cells.

开始日期2024-12-04

申办/合作机构

Sutro Biopharma, Inc.

[+1]

NCT06555263

/ Recruiting临床2期

A Phase 2, Open-label Study Evaluating STRO-002, an Anti-folate Receptor Alpha (FOLR1) Antibody-Drug Conjugate, in Subjects with Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Expressing FOLR1

A Phase 2 study evaluating STRO-002 in subjects with previously treated advanced or metastatic non-small cell lung cancer expressing FOLR1

开始日期2024-08-21

申办/合作机构

Sutro Biopharma, Inc.

NCT06238687

/ Recruiting临床1/2期

A Phase I/IIa Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Preliminary Efficacy of STRO-002 in Chinese Adults With Advanced Epithelial Ovarian Cancer, Endometrial Cancer, and Other Advanced Malignant Solid Tumors.

This is a multi-center, open-label, monotherapy dose escalation, PK bridging, and dose expansion Phase I/IIa study in Chinese adult subjects to evaluate the safety, tolerability, Pharmacokinetics (PK) profiles, immunogenicity, and preliminary efficacy of STRO-002 in patients with advanced malignant solid tumors.

开始日期2023-11-08

申办/合作机构

天士力医药集团股份有限公司

[+1]

100 项与 Luveltamab Tazevibulin 相关的临床结果

登录后查看更多信息

100 项与 Luveltamab Tazevibulin 相关的转化医学

登录后查看更多信息

100 项与 Luveltamab Tazevibulin 相关的专利（医药）

登录后查看更多信息

3

项与 Luveltamab Tazevibulin 相关的文献（医药）

2023-05-01·American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Antibody-Drug Conjugates in Gynecologic Cancer.

Review

作者: Powell, Sachia Stonefeld ; Pothuri, Bhavana ; Karpel, Hannah C

The present article reviews the current evidence for antibody-drug conjugates (ADCs) in gynecologic cancer. ADCs consist of a highly selective monoclonal antibody for a tumor-associated antigen and a potent cytotoxic payload conjugated through a linker. Overall, the toxicity profiles of ADCs are manageable. Ocular toxicity is a known class effect of some ADCs and is managed with prophylactic corticosteroid and vasoconstrictor eye drops as well as dose interruptions/holds and dose modifications. In ovarian cancer, mirvetuximab soravtansine, an ADC targeting alpha-folate receptor (FRα), received US Food and Drug Administration (FDA) accelerated approval in November 2022 after data from the single-arm phase III SORAYA trial. A second ADC targeting FRα, STRO-002, received FDA fast track designation in August 2021. Multiple studies with upifitamab rilsodotin, an ADC comprising a NaPi2B-binding antibody, are underway. In cervical cancer, tisotumab vedotin, an ADC-targeting tissue factor, received FDA accelerated approval in September 2021 after the phase II innovaTV 204 trial. Tisotumab vedotin in combination with chemotherapy and other targeted agents is currently being evaluated. Although there are no currently approved ADCs for endometrial cancer, there are many under active evaluation, including mirvetuximab soravtansine. Trastuzumab-deruxtecan (T-DXd), an ADC targeting human epidermal growth factor receptor 2 (HER2), is currently approved for HER2-positive and HER2-low breast cancer and shows promise in endometrial cancer. Like all anticancer treatments, the decision for a patient to undergo therapy with an ADC is a personal choice that balances the potential benefits with the side effects and requires thorough and compassionate support of their physician and care team and shared decision making.

2023-02-01·Molecular cancer therapeutics

Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers

Article

作者: Stephenson, Heather T. ; Abrahams, Cristina L. ; Bedard, Kristin ; Hallam, Trevor J. ; Bajjuri, Krishna ; Hanson, Jeffrey ; Henningsen, Robert ; Tran, Cuong ; Zhou, Sihong ; Stafford, Ryan L. ; Calarese, Daniel ; Li, Xiaofan ; Yin, Gang ; Sato, Aaron K. ; Krimm, Stellanie ; Smith, Jennifer ; Yam, Alice Y. ; Lupher, Mark Jr. ; Heibeck, Tyler H. ; Kline, Toni ; De Almeida, Venita I.

Abstract:

STRO-002 is a novel homogeneous folate receptor alpha (FolRα) targeting antibody–drug conjugate (ADC) currently being investigated in the clinic as a treatment for ovarian and endometrial cancers. Here, we describe the discovery, optimization, and antitumor properties of STRO-002. STRO-002 was generated by conjugation of a novel cleavable 3-aminophenyl hemiasterlin linker-warhead (SC239) to the nonnatural amino acid para-azidomethyl-L-phenylalanine incorporated at specific positions within a high affinity anti-FolRα antibody using Sutro's XpressCF+, which resulted in a homogeneous ADC with a drug–antibody ratio (DAR) of 4. STRO-002 binds to FolRα with high affinity, internalizes rapidly into target positive cells, and releases the tubulin-targeting cytotoxin 3-aminophenyl hemiasterlin (SC209). SC209 has reduced potential for drug efflux via P-glycoprotein 1 drug pump compared with other tubulin-targeting payloads. While STRO-002 lacks nonspecific cytotoxicity toward FolRα-negative cell lines, bystander killing of target negative cells was observed when cocultured with target positive cells. STRO-002 is stable in circulation with no change in DAR for up to 21 days and has a half-life of 6.4 days in mice. A single dose of STRO-002 induced significant tumor growth inhibition in FolRα-expressing xenograft models and patient-derived xenograft models. In addition, combination treatment with carboplatin or Avastin further increased STRO-002 efficacy in xenograft models. The potent and specific preclinical efficacy of STRO-002 supports clinical development of STRO-002 for treating patients with FolRα-expressing cancers, including ovarian, endometrial, and non–small cell lung cancer. Phase I dose escalation for STRO-002 is in progress in ovarian cancer and endometrial cancer patients (NCT03748186 and NCT05200364).

2022-11-22·Blood advances

Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1–antibody-drug conjugate

Article

作者: Brodersen, Lisa Eidenshinck ; Abrahams, Cristina ; Bedard, Kristin ; Kirkey, Danielle ; Le, Quy ; Tang, Thao ; Loken, Michael R. ; Pardo, Laura ; Meshinchi, Soheil ; Perkins, LaKeisha ; Tarlock, Katherine ; Castro, Sommer ; Molina, Arturo ; Smith, Jenny ; Loeb, Keith R. ; McKay, Cyd Nourigat

We identified the FOLR1 transcript to be uniquely expressed in CBF/GLIS AML but silent in most other types of AML, normal CD34+ cells, and bone marrow samples.Here, we present preclin. studies on the efficacy of STRO-002, a FOLR1-directed antibody-drug conjugate (ADC), developed by Sutro Biopharma for solid malignancies against CBF/GLIS AML.To evaluate the specificity of STRO-002 against FOLR1-pos. AML, MV4;11 AML cells were transduced with a FOLR1- expressing construct (MV4;11 FOLR1+).The viability of MV4;11 FOLR1+ cells and parental MV4;11 cells lacking FOLR1 expression was determined after incubation with increasing concentrations of STRO-002.To assess the activity of STRO-002 in xenograft mouse models, we first transplanted MV4;11 FOLR1+ cells transduced with green fluorescent protein/firefly luciferase into NOD/SCID/IL2rγnull NOD scid gamma(NSG) mice.The mice that underwent transplantation received 3 weekly doses of STRO-002 at 2.5 mg/kg and 5 mg/kg 1 wk after transplantation.In addition, STRO-002 therapy resulted in stable complete remission, with treated mice surviving up to the end of the study (112 days) compared with untreated MV4;11 FOLR1+ xenograft mice, which developed progressive disease and had a median survival of 52 days after receiving injection for leukemia (P = .002).In this study, we show that FOLR1 is uniquely expressed in CBF/ GLIS AML but silent in normal cells, providing a strategy to target leukemia cells without affecting normal hematopoiesis. FOLR1 is targeted by STRO-002, an ADC that is currently in a phase 1 clin. trial for the treatment of solid tumors.We demonstrate that STRO-002 exhibits target-dependent cytotoxicity against FOLR1-expressing AML cells.STRO-002 therapy is highly effective against MV4;11 FOLR1+ and CBF/GLIS-CB but has only modest activity against the CBF/GLIS-pos. WSU-AML cell line expressing lower levels of FOLR1.In conclusion, we have shown that preclin. studies with STRO-002, a FOLR1-directed ADC, can effectively eliminate CBF/GLISpos. AML, providing a promising approach to treating this aggressive pediatric leukemia.

126

项与 Luveltamab Tazevibulin 相关的新闻（医药）

2025-03-25

·循因缉药

涉及普方生物-艾伯维状告Genmab

2025年3月22日，丹麦制药巨头Genmab发布公告： Genmab将坚决捍卫针对AbbVie公司提出的商业机密侵权指控。呃，这是咋了？跟普方（ProfundBio）又有毛线关系？别急，马上来。 #01 咋了？据fiercebio报道， AbbVie指责其对ProfoundBio的抗体药物偶联物（ADC）技术中窃取AbbVie商业机密的行为“故意视而不见”。 AbbVie声称ProfoundBio（普方生物）通过前员工Julia Gavrilyuk博士获取了其商业机密，从而在ADC开发上取得进展。 Genmab在以18亿美元收购ProfoundBio时，应意识到其技术基于AbbVie的商业机密。有同学要问了，你咋不直接找个起诉书好好看看.. 呃，找到了，但是要钱...所以，你知道我的。这里面的关键是： Gavrilyuk博士与Tae Han博士曾在Stemcentrx和AbbVie共事，Han博士后来共同创立了ProfoundBio。诉讼称Han博士知道Gavrilyuk博士在AbbVie的工作涉及ProfoundBio所需的ADC连接子技术。那么他们俩真的有交集吗？ #03 普方三巨头普方成立于2018年，主要从事ADC（抗体偶联药物）开发。三位核心创始人赵柏腾、韩泰熙（Tae Han）以及尚晓，均出自ADC先驱Seagen公司。这是对媒体的一般性介绍，但是这里面其实有问题。这里面除了赵柏腾一直待在Seagen直到创立普方外，其他两位联合创始人其实早就离开Seagen了。尚晓在2012年就离开了Seagen，加入盛诺基医药担任高级副总裁。而韩泰熙则是在2014年离开Seagen加入Stemcentrx，从事临床药理/药代动力学方面的工作。随后，2016年，Stemcentrx被Abbive（艾伯维收购）顺势归属Abbive。在参与创立PorfundBio之前，还有一段短暂的从业经历。 Julia Gavrilyuk是韩泰熙在Stemcentrx的老同事，被收购后待在Abbive一直干到2020年才离开。与韩泰熙不同，Julia确实是从事化学研究，理论上确实能够接触到Linker的研究。但是，我们不是司法部门，更不能做任何推断。回过头，我们再来看Abbive对普方的指控。 #03 18亿美元宝贝普方生物成立于2018年，苏州公司注册成立于2019年。 2021年2月公告完成了千万级Pre-A融资，随后一路高歌猛进，直至2024年被Genmab以18亿美元收购。其管线进展最快的要数PRO1184(Rina-S），这是一款针对实体瘤叶酸受体（FRα）靶点的ADC。呃，诸位是不是想起了一位故人... 没错，与Sutro刚刚失败的STRO-002是一个靶点。呃，没有暗示普方这个不行啊，同一个靶点有人成功有人失败很正常。 PRO1184使用的是普方专利的新型亲水连接子偶联exatecan，DAR=8。这个linker普方申请专利号为WO2023280227，2022年申请，2023年公开。更早的相关专利EP-4366777-A2于2021年7月5日申请。而AbbVie声称ProfoundBio在无法独立开发ADC管线后，通过前员工Julia Gavrilyuk博士获取了AbbVie的商业机密和保密信息，从而扭转了局面，开始申请专利并推进临床管线。这个时间线能不能卡的上，在看到更多信息之前谁也不好说。反正，这18亿美元的大宝贝Genmab是买到手了，让他头疼吧。 #04 最后 Genmab明确否认AbbVie的指控，并将积极应诉。 Genmab指出，这是AbbVie近期针对竞争对手提起的多起类似商业机密侵权诉讼中的又一起。这并不是Genmab故意搅浑水，Abbive最近的诉讼确实不少。根据Firecebio的统计，Adcentrx, Alvotech, BeiGene 和Revance 都因为类似的原因被Abbive送上法庭... 好吧，甭管赢不赢，能迟滞下对手也是好事嘛。好吧...咱们走着瞧吧。今天的瓜先吃到这里，明天的瓜咱们明天再吃。 END 找小编，扫这里！至此，各位股东星标了么？点赞了么？转发了么？在看了么？谢谢！所有内容均不作为投资建议，信息均来自公开资料，星球更新更快。近期文章：学术的尽头是发币？ 23andMe申请破产保护！创始人兼CEO出局！ Human Longevity|为什么同样的事他们说就显得这么高级？这么大的事你不宣传？金斯瑞你糊涂啊！ CACLP之测序仪新品的悄悄上新 Akoya：2024Q4多少有点潦草相关资料：注1：https://www.fiercebiotech.com/biotech/abbvie-takes-genmab-court-accusing-its-partner-being-willfully-blind-adc-trade-secret-theft注2：https://ir.genmab.com/news-releases/news-release-details/genmab-vigorously-defend-alleged-claims-trade-secret/注3：https://www.pacermonitor.com/public/case/57357486/AbbVie_Inc_v_Genmab_AS_et_al注4：https://wallstreetcn.com/articles/3712431

并购抗体药物偶联物引进/卖出

2025-03-16

·PipelineReview

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

– The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater – SOUTH SAN FRANCISCO, CA, USA I March 15, 2025 I Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced expanded data in a late-breaking oral presentation from the dose-optimization portion of the REFRαME-O1 trial with luveltamab tazevibulin (luvelta) in patients with platinum resistant ovarian cancer (PROC) at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer ® . The SGO Annual Meeting will take place from March 14-17, 2025 in Seattle, Washington. In this study, luvelta demonstrated encouraging antitumor activity in patients with late-stage ovarian cancer across all levels of Folate Receptor-α (FRα) expression of 25% or greater, including an improved overall response rate (ORR), a low discontinuation rate, and a consistent safety profile across dose levels. Based on these findings, Sutro selected the optimized dose of luvelta: 5.2 mg/kg + G-CSF for two cycles then continued on 4.3 mg/kg. “These data demonstrate the potential for improved patient responses compared to standard chemotherapy in PROC, especially patients whose FRα expression falls within the range of at least 25% to less than 75% 2+, which remains an important unmet medical need,” commented Dr. Jung Yun Lee, Professor, Gynecologic Oncologist, Yonsei Cancer Center and Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Late-Breaking Oral Presentation Highlights: The presentation will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com . The Company recently announced that it is deprioritizing investment into the development of luvelta across all indications. Sutro continues to explore out-licensing opportunities to deliver the promise of luvelta’s benefit to patients with unmet need in platinum resistant ovarian cancer and beyond. 1 Immediately after data extraction, one additional patient experienced a confirmed PR and is included in the analysis. About Luveltamab Tazevibulin Luveltamab tazevibulin, abbreviated as “luvelta” and formerly known as STRO-002, is a FRα-targeting antibody-drug conjugate (ADC) designed to treat a broad range of patients with ovarian cancer, including those with lower FRα-expression who are not eligible for approved treatment options targeting FRα. Developed and manufactured with Sutro’s cell-free XpressCF ® platform, luvelta is a homogeneous ADC with four hemiasterlin cytotoxins per antibody, precisely positioned to efficiently deliver to the tumor while ensuring systemic stability after dosing. The U.S. Food and Drug Administration (FDA) has granted luvelta a Fast Track designation for Ovarian Cancer, as well as Orphan and Rare Pediatric Disease designations for CBF/GLIS2 Pediatric AML. About Sutro Biopharma Sutro Biopharma, Inc., is relentlessly focused on the discovery and development of precisely designed cancer therapeutics to transform what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF ® , provides the opportunity for broader patient benefit and an improved patient experience. Sutro is advancing a robust early-stage pipeline of novel exatecan and dual-payload antibody drug conjugates (ADCs), coupled with high-value collaborations and industry partnerships, which validate its continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com . SOURCE: Sutro Biopharma

快速通道ASCO会议抗体药物偶联物临床结果

2025-01-10

·米内网

【瞩目】天士力1类新药亮相！猛攻2300亿市场

精彩内容 2025年1月10日，CDE官网显示，天士力的生物药1类新药P134细胞注射液申报IND获受理。米内网数据显示，2023年中国三大终端六大市场（统计范围详见本文末）生物药销售额超过2300亿元，目前公司已有9款1类新药亮相。 P134细胞注射液是一款生物药1类新药，为天士力2025年首款申报IND的创新药。米内网数据显示，近年来中国三大终端六大市场生物药销售额逐年上涨，2022年突破2000亿元，2023年超过2300亿元，2024上半年以约4%的增速继续增长，全年销售额有望再创新高。近年来中国三大终端六大市场生物药销售情况（单位：万元）来源：米内网格局数据库 2024上半年生物药TOP10产品中，贝伐珠单抗注射液、注射用曲妥珠单抗、利妥昔单抗注射液、替雷利珠单抗注射液、信迪利单抗注射液等抗体药物，GLP-1受体激动剂司美格鲁肽注射液等上榜。2024H1中国三大终端六大市场生物药TOP10产品来源：米内网格局数据库生物药是天士力重点布局的方向之一，公司开发的特异性溶栓重磅产品注射用重组人尿激酶原已获批上市，适应症从急性ST段抬高型心肌梗死（心梗）拓展至急性缺血性脑卒中（脑梗）。此外，据不完全统计，目前天士力有9款生物药1类新药在国内处于申报临床及以上阶段（不含已上市/暂停研发的品种），包括多款干细胞疗法。天士力国内部分在研的生物药新药来源：米内网综合数据库从研发进展看，PD-L1/VEGF双抗B1962注射液、治疗用乙型肝炎腺病毒注射液、FRα ADC药物STRO-002注射液正在开展II期临床（含I/IIa期）；培重组人成纤维细胞生长因子21注射液NASH适应症FDAI期临床完成全部入组，国内已获批临床；治疗慢性心力衰竭的人脐带间充质干细胞注射液获批临床等。近年来，天士力坚定实施创新驱动战略，持续加大研发投入。2023年公司研发投入13.15亿元，同比增长29.49%，占医药工业收入比例为17.73%。2024前三季度研发费用（不含资本化投入）约5.6亿元。在过去的2024年，天士力产品研发进展不断：生物药新药注射用重组人尿激酶原新适应症提交NDA，用于治疗急性缺血性脑卒中；枇杷清肺饮颗粒、温经汤颗粒2款中药3.1类新药（古代经典名方中药复方制剂）报产；1类新药人脐带间充质干细胞注射液获批临床，1类新药同种异体脂肪间充质基质细胞注射液申报IND获受理等。资料来源：米内网数据库、CDE等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至2025年1月10日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 ●温馨提示● 因为微信公众号修改了推送规则，最近很多读者反映没有及时看到推文。把米内网设为“星标”，就能每天与我们不见不散啦，具体操作如下：【分享、点赞、在看】点一点不失联哦

临床申请申请上市抗体药物偶联物细胞疗法

100 项与 Luveltamab Tazevibulin 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
输卵管癌	临床3期	美国	Sutro Biopharma, Inc.	2023-07-12
输卵管癌	临床3期	澳大利亚	Sutro Biopharma, Inc.	2023-07-12
输卵管癌	临床3期	加拿大	Sutro Biopharma, Inc.	2023-07-12
输卵管癌	临床3期	以色列	Sutro Biopharma, Inc.	2023-07-12
输卵管癌	临床3期	新西兰	Sutro Biopharma, Inc.	2023-07-12
输卵管癌	临床3期	新加坡	Sutro Biopharma, Inc.	2023-07-12
输卵管癌	临床3期	韩国	Sutro Biopharma, Inc.	2023-07-12
卵巢上皮癌	临床3期	美国	Sutro Biopharma, Inc.	2023-07-12
卵巢上皮癌	临床3期	澳大利亚	Sutro Biopharma, Inc.	2023-07-12
卵巢上皮癌	临床3期	加拿大	Sutro Biopharma, Inc.	2023-07-12

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05870748 (REFRαME-O1, PipelineReview) 人工标引	临床2/3期	铂耐药性卵巢癌 FRα expression	-	Luveltamab Tazevibulin 5.2 mg/kg	餘積憲衊蓋蓋製積膚襯(窪獵齋範選醖憲築積淵) = 醖鏇鑰壓衊觸選衊簾鬱顧繭遞製衊願選鏇網鹹 (顧築淵襯鹹選齋夢遞簾 ) 更多	积极	2025-03-16
				Luveltamab Tazevibulin 4.3 mg/kg	餘積憲衊蓋蓋製積膚襯(窪獵齋範選醖憲築積淵) = 壓艱窪鹽淵遞鏇壓簾繭顧繭遞製衊願選鏇網鹹 (顧築淵襯鹹選齋夢遞簾 ) 更多
NCT05200364 (STRO-002-GM2, ESMO2024) 人工标引	临床1期	复发性卵巢癌	18	Luveltamab tazevibulin	顧襯壓範鑰淵襯築窪膚(鹹糧範獵壓繭壓膚選憲) = One pt (5.2 mg/kg) had 2 DLTs (G3 nausea and G4 decreased appetite). 築積膚範憲夢構蓋鬱鬱 (夢築憲製窪顧衊遞構鹽 ) 更多	积极	2024-09-14
				Luveltamab tazevibulin (Bev naive)
ASH2023 人工标引	N/A	急性髓性白血病	25	Luveltamab Tazevibulin	構蓋鏇鹽鬱襯鑰製艱廠(範顧積簾蓋醖淵網鏇壓) = 積網遞窪觸淵壓淵繭糧憲襯夢範憲觸選艱蓋夢 (選蓋積觸範壓壓簾膚夢 ) 更多	积极	2023-12-11
NEWS 人工标引	临床1期	子宫内膜癌	16	Luveltamab Tazevibulin (TPS ≥1% FolRα expression)	簾衊遞繭齋構夢襯築齋(醖積鏇鬱簾願遞窪壓窪) = 窪淵窪顧憲網襯鏇築鑰憲鏇遞衊鹽遞顧窪膚積 (廠夢憲鏇遞衊餘壓築鏇 ) 更多	积极	2023-10-22
				Luveltamab Tazevibulin (TPS >25% FolRα expression)	簾衊遞繭齋構夢襯築齋(醖積鏇鬱簾願遞窪壓窪) = 醖鹽簾築鹹鑰窪積鬱鑰憲鏇遞衊鹽遞顧窪膚積 (廠夢憲鏇遞衊餘壓築鏇 ) 更多
NCT03748186 (STRO-002-GM1 , ESMO 12023 \| ESMO 22023) 人工标引	临床1期	子宫内膜癌	17	Luveltamab tazevibulin	襯醖膚餘衊廠糧簾淵壓(構觸齋築網夢構鹽簾繭) = 鹹窪鬱觸醖膚窪衊襯夢蓋網淵艱遞夢製簾廠願 (鏇遞蓋壓鑰夢構鹹醖窪 ) 更多	积极	2023-10-22
				Luveltamab tazevibulin (recurrent/progressive epithelial endometrial cancer (EEC) FolRα ≥ 25%)	襯醖膚餘衊廠糧簾淵壓(構觸齋築網夢構鹽簾繭) = 築繭鹽築憲窪餘餘鹽蓋蓋網淵艱遞夢製簾廠願 (鏇遞蓋壓鑰夢構鹹醖窪 ) 更多
NCT03748186 (STRO-002-GM1, ASCO2023) 人工标引	临床1期	卵巢上皮癌	44	Luveltamab tazevibulin 4.3 mg/kg	繭鬱繭蓋窪網簾觸願憲(窪膚鹹蓋簾蓋廠積網鑰) = The most common grade ≥ 3 treatment emergent adverse events (TEAEs) included neutropenia (70.5%), arthralgia (18.2%), and anemia (13.6%). G3/4 neutropenia had a higher incidence at 5.2 mg/kg than 4.3 mg/kg (76% vs 65%); most notable for G4 neutropenia (52% vs 22%). 窪鑰選築醖齋願襯積簾 (齋簾鑰獵鑰糧觸鬱衊積 )	积极	2023-05-31
				Luveltamab tazevibulin 5.2 mg/kg
NCT03748186 (STRO-002-GM1, PipelineReview) 人工标引	临床1期	卵巢癌 FolRα-selected	-	STRO-002 (FolRα-selected)	艱襯鹹蓋觸廠築獵網夢(淵窪觸鹽簾壓獵蓋鏇窪) = 衊鬱顧選壓製憲憲衊築簾觸鬱衊遞壓醖窪憲夢 (製製夢膚鏇範襯淵鏇艱 ) 更多	积极	2023-01-09
				STRO-002 (unselected for FolRα)	艱襯鹹蓋觸廠築獵網夢(淵窪觸鹽簾壓獵蓋鏇窪) = 選簾構窪鹹窪製糧積顧簾觸鬱衊遞壓醖窪憲夢 (製製夢膚鏇範襯淵鏇艱 ) 更多
NCT03748186 (STRO-002-GM1, ASCO2021)	临床1期	铂耐药性卵巢癌	39	STRO-002	廠憲壓觸簾糧蓋憲鬱鹹(艱築壓齋憲簾選憲夢夢) = 12.8% 積糧製醖糧遞糧齋憲鏇 (窪鏇蓋壓壓壓艱糧蓋餘 ) 更多	积极	2021-05-28
NCT03748186 (138, IGCS2020)	临床1期	铂耐药上皮性卵巢癌 FRÎ±	38	STRO-002	壓廠製鏇積製積窪壓繭(製窪鏇襯窪簾鏇憲簾醖) = 艱製鑰憲遞範簾選窪窪齋齋選憲壓齋網糧積積 (壓願醖範鏇齋積範選鏇 ) 更多	积极	2020-11-13